Abiraterone Krka

abiraterone acetate

Table of contents

Opinion

On 22 April 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Abiraterone KRKA, intended for the treatment of metastatic prostate cancer.

The applicant for this medicinal product is KRKA, d.d., Novo mesto.

Abiraterone KRKA will be available as 500 mg film-coated tablet. The active substance of Abiraterone KRKA is abiraterone acetate, a hormone antagonist (ATC code: L02BX03) that inhibits the production of androgens in the testes, adrenal glands and prostatic tumour tissues.

Abiraterone KRKA is a generic of Zytiga, which has been authorised in the EU since 05/09/2011. Studies have demonstrated the satisfactory quality of Abiraterone KRKA, and its bioequivalence to the reference product Zytiga. A question and answer document on generic medicines can be found here.

The full indication is:

Abiraterone KRKA is indicated with prednisone or prednisolone for:

  • the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
  • the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
  • the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Abiraterone KRKA should be prescribed by an appropriate healthcare professional.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Key facts

Name
Abiraterone Krka
Agency product number
EMEA/H/C/005649
International non-proprietary name (INN) or common name
  • abiraterone acetate
Active substance
  • abiraterone acetate
Therapeutic area
Prostatic Neoplasms
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Date opinion adopted
22/04/2021
Company name
Krka, d.d., Novo mesto
Status
Positive
Application type
Initial authorisation

How useful was this page?

Add your rating